This is a promotional meeting organised and funded by Roche Products Ltd.

Prescribing Information:

Tecentriq®(atezolizumab) 

TECENTRIQ, in combination with bevacizumab, paclitaxel and caboplatin, is intended for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, TECENTRIQ, in combination with bevacizumab, paclitaxel and caboplatin, is indicated only after failure of appropriate targeted therapies.

Avastin® (bevacizumab) 

Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

For the past decade, Roche has brought together the lung cancer community to share expertise, knowledge and solutions to the ever-changing treatment landscape of lung cancer. Last year we launched the Virtual Lung Cancer Expert Forum as a supplementary learning experience to our flagship meeting. In 2020 we are continuing this initiative with a number of virtual meetings.

We are in challenging times at present and are truly grateful for the difference you are making to the lives of patients during the Covid-19 pandemic. At Roche we feel that providing quality education is still important and therefore would like you to join us for a virtual meeting, in which we will explore various aspects of lung cancer treatment and share expertise from across the community.

A virtual meeting uses live, online interactive technology to allow delegates to access a meeting remotely. You can join the online presentations and ask text-based questions to be answered in the Q&A session at the end of each meeting.

This is an innovative way to learn about recent developments in treatments of lung cancer and to support best practice learning across the community.

SESSION 1

Tuesday 6th October 2020
18:30 – 19:45 BST

Webinar: Clinical conundrums: Is it time to change our approach to treating liver metastases in 1L non-squamous NSCLC?

Agenda

18:30 – 18:50

Welcome and Introduction. Why liver metastases should be treated differently.

In this session, Professor Samreen Ahmed will discuss the pathophysiology of
liver metastatic disease and provide an overview of the efficacy data from the IMpower 150 trial.

 

18:50 – 19:10

Appropriate patient selection, real world experience including case studies.

In this session, Dr Tim Benepal will discuss his approach to selecting appropriate patients for the IMpower150 regimen (Tecentriq ®▼ (atezolizumab), in combination with Avastin (bevacizumab), paclitaxel and carboplatin), as well as the safety and quality of life data from the IMpower150 trial. This will be followed by Professor Samreen Ahmed & Dr Tim Benepal discussing their experience of the regimen with some patient case studies.

 

19:10 – 19:25

The threshold to treat: when does a metastatic site become actionable?

In this session, Dr Tim Benepal will discuss his clinical experience in treating non-squamous NSCLC patients with varying degrees of liver metastases.

 

19:25 – 19:40

Questions and Answers

Professor Samreen Ahmed and Dr Tim Benepal

 

19:45

Meeting Close

Professor Samreen Ahmed

Speakers

Dr Tim Benepal

Consultant Medical Oncologist
St George’s Hospital London

Professor Samreen Ahmed

Consultant Medical Oncologist
Leicester Royal Infirmary

Dr Tim Benepal

Consultant Medical Oncologist
St George’s Hospital London

Dr Tim Benepal is a consultant medical oncologist at St George’s University Hospitals NHS Trust, London. He completed his medical training at University College Hospital, London in 1993. After working and training in general medicine for several years, he moved to the Chelsea & Westminster Hospital. Dr Benepal carried out his oncology training at the Royal Marsden, Guy’s and St Thomas’ Hospitals, as well as undertaking a significant period of research in anti-folates, at The Institute of Cancer Research. He has been an oncologist for the last 22 years, the last 13 of which have been as a consultant at St George’s Hospital.

Professor Samreen Ahmed

Consultant Medical Oncologist
Leicester Royal Infirmary

Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester 2016.

Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and Principal Investigator for a number of clinical trials in breast and lung cancer, and a member of NCRI lung CSG and BTOG Steering Group.

REGISTER



M-GB-00001242
September 2020

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. As TECENTRIQ and Avastin are a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

This is a promotional meeting organised and funded by Roche Products Ltd.

The link you have selected will take you away from this site to one that is not owned or controlled by Roche Products Ltd. Roche Products Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.